201 Redwood Shores Parkway
Suite 315
Redwood City, CA 94065
United States
650 206 4507
https://www.rezolutebio.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 57
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Nevan Charles Elam J.D. | Founder, CEO & Acting Chairman of the Board | 973.65k | N/A | 1967 |
Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer | 738.86k | N/A | 1975 |
Mr. Daron G. Evans M.B.A., M.S. | Chief Financial Officer | N/A | N/A | 1974 |
Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific & Patient Affairs | N/A | N/A | N/A |
Mr. Michael R. Deperro | Senior VP & Head of Corporate Development | N/A | N/A | N/A |
Mr. Michael Covarrubias | Senior VP & Head of Program & Portfolio Management | N/A | N/A | N/A |
Mr. Chris Milks | VP & Head of Finance | N/A | N/A | N/A |
Dr. Raj Agrawal M.D. | VP & Head of Ophthalmological Clinical Development | N/A | N/A | N/A |
Ms. Robyn Sweinhart | VP & Head of Quality | N/A | N/A | N/A |
Ms. Erin O'Boyle | Senior VP & Head of Clinical Operations | N/A | N/A | N/A |
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.